Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Buildings Capital Leases Cash & Equivalents Common Equity Construction in Progress Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Amphastar Pharmaceuticals (AMPH) Intangibles (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 4 years of Intangibles data on record, last reported at $29.2 million in Q4 2022.

For Q4 2022, Intangibles changed N/A year-over-year to $29.2 million; the TTM value through Dec 2022 reached $29.2 million, changed N/A, while the annual FY2022 figure was $29.2 million, N/A changed from the prior year.
Intangibles reached $29.2 million in Q4 2022 per AMPH's latest filing, down from $30.6 million in the prior quarter.
Across five years, Intangibles topped out at $29.2 million in Q4 2022 and bottomed at $29.2 million in Q4 2022.